Data present at conference supports the value of potential HAE treatment, deucrictibant

The potential of an as yet unapproved HAE treatment, called deucrictibant, was demonstrated in a series of data presentations at the recent American Academy of Allergy, Asthma and Immunology 2026 Annual Meeting. The summary of the data is:

• Data from a key Phase-3 study (RAPIDe-3) showed that deucrictibant achieved onset of symptom relief in 1.28 hours and complete symptom resolution in 11.95 hours
• Final data from the CHAPTER-1 study gave further evidence on the long-term safety and efficacy of deucrictibant for the prevention of HAE attacks, and that a deucrictibant extended-release tablet could be valuable for once-daily prophylaxis

Peng Lu MD PhD, Chief Medical Officer of Pharvaris, said: “The RAPIDe-3 data confirm the robust and consistent clinical effects of deucrictibant across our primary and all 11 secondary efficacy endpoints versus placebo, confirming its potentially differentiated profile for the treatment of all types of HAE attacks. Due to its mechanism of action, deucrictibant is expected to out-compete bradykinin at the B2 receptor, resulting in direct modulation of bradykinin signaling, as demonstrated by the rapid and sustained symptom relief and attack resolution findings from RAPIDe-3. We are pleased to present these pivotal data at AAAAI and look forward to future exchanges with the HAE community about deucrictibant’s potential to become standard of care in the treatment of HAE attacks.”

(Source: Pharvaris)